Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01408082 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of a Steroid/Antibiotic Combination Eyedrop to Treat Non-Bacterial Blepharitis
A Phase 3 study, sponsored by Sun Pharmaceutical Industries Limited.
- Completed
- Registry status
- Phase 3
- Development phase
- 917
- Enrollment target
NCT01408082 is a Phase 3 study that has completed, run by Sun Pharmaceutical Industries Limited. The registered enrollment target is 917 participants.
The verdict
NCT01408082, a Phase 3 study, has completed, sponsored by Sun Pharmaceutical Industries Limited.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 917 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the clinical efficacy and safety of ISV-502 compared to AzaSite® alone, Dexamethasone alone, and vehicle in the treatment of subjects with Non-bacterial Blepharitis.
Interventions
- DRUG Dexamethasone
- OTHER Vehicle
- DRUG Azasite
- DRUG ISV-502 (1.0% azithromycin and 0.1% dexamethasone combined)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 917 participants |
| Start Date | 2011-10 |
| Est. Completion | 2013-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01408082
The ClinicalTrials.gov registry entry for NCT01408082 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 917 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sun Pharmaceutical Industries Limited, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Dexamethasone is the first listed.
NCT01408082 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01408082 about?
NCT01408082 is a clinical study titled "Efficacy and Safety Study of a Steroid/Antibiotic Combination Eyedrop to Treat Non-Bacterial Blepharitis". The purpose of this study is to evaluate the clinical efficacy and safety of ISV-502 compared to AzaSite® alone, Dexamethasone alone, and vehicle in the treatment of subjects with Non-bacterial Blepharitis.
What is the current status of trial NCT01408082?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 917 participants. The study started on 2011-10. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01408082?
The interventions under investigation include: Dexamethasone (DRUG), Vehicle (OTHER), Azasite (DRUG), ISV-502 (1.0% azithromycin and 0.1% dexamethasone combined) (DRUG).
Who is sponsoring clinical trial NCT01408082?
This trial is sponsored by Sun Pharmaceutical Industries Limited, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.